Peptides for Fat Loss: GLP-1, Fragment 176-191, AOD-9604, and Growth Hormone Research
Multiple peptide classes address fat loss through different mechanisms: GLP-1 agonists (appetite suppression), GH fragment peptides (lipolysis), and GHRH/GHS stacks (GH-driven fat metabolism). This guide reviews the research evidence across each category and what they show for adipose tissue reduction.
Fat loss peptide research spans multiple mechanistic targets: GLP-1 receptor agonists for appetite suppression, GH fragment lipolysis, and GH secretagogue-driven body composition shifts. This article reviews the evidence hierarchy across approaches.
GLP-1 Receptor Agonists: Dominant Class
Semaglutide is the most clinically validated peptide for fat loss. The STEP 1 trial (Wilding JPH et al., *NEJM*, 2021, n=1961):
- Mean body weight reduction: 14.9% vs 2.4% placebo at 68 weeks
- ≥15% weight loss achieved: 32% of semaglutide vs 2% placebo
- Waist circumference: −13.5 cm vs −4.1 cm
Mechanism: GLP-1R activation in the hypothalamus reduces food intake through satiety signalling and appetite suppression; peripheral delayed gastric emptying increases meal satiety.
Tirzepatide (GLP-1/GIP dual agonist) achieves even greater weight loss: −20.9% at 72 weeks with 15 mg weekly in SURMOUNT-1 (Jastreboff AM et al., *NEJM*, 2022) — the highest efficacy in any randomised anti-obesity pharmaceutical trial.
AOD-9604: GH Fragment Lipolysis
AOD-9604 is the C-terminal 16-amino acid fragment of hGH (residues 176-191), isolated for lipolytic activity without growth-promoting or insulin-like effects. Mechanism: β3-adrenergic receptor activation in adipocytes → hormone-sensitive lipase stimulation → lipolysis.
In *ob/ob* obese mice: 25-50% greater fat mass reduction vs saline controls at 1 mg/kg/day for 6 weeks, with lean mass unchanged.
However, Phase 3 human clinical trials failed to meet the primary weight loss endpoint. The dramatic rodent β3-AR pharmacology does not replicate in humans due to lower adipose β3-AR expression and coupling efficiency.
GH Secretagogues: Body Composition Shifts
CJC-1295 (no DAC) + Ipamorelin elevates GH and IGF-1, producing GH-mediated visceral fat mobilisation:
- Reduction in visceral fat: 3-7% over 6 months in GH-deficient adults
- Lean mass increase: 2-3% over same period
- Effect on total weight: minimal (fat loss offset by lean mass gain)
GH preferentially targets visceral adipocytes (higher GH receptor density) vs subcutaneous fat.
Evidence Hierarchy Summary
| Approach | Primary Mechanism | Human Evidence Quality |
|---|---|---|
| GLP-1 agonists | Central appetite suppression | Phase 3 RCTs, FDA-approved |
| GH secretagogues | GH-driven visceral lipolysis | Limited clinical trials |
| AOD-9604 | β3-AR adipocyte lipolysis | Phase 3 failure |
All peptides except GLP-1 agonists and tirzepatide are research compounds or regulated pharmaceuticals requiring medical supervision.
<!-- deep-links-v1 -->
Expanded Metabolic Peptide Research Landscape
The GLP-1/Fragment/GH approach to fat loss intersects with a wide range of additional compounds under active research. Adipotide (FTPP) is a pro-apoptotic peptide targeting vasculature supplying white adipose tissue, with a mechanism entirely distinct from receptor agonism. Retatrutide, a triple agonist at GIP, GLP-1, and glucagon receptors, represents the most recent generation of multi-target metabolic peptides. Cagrilintide, a long-acting amylin analogue, is studied in combination with semaglutide for additive weight loss through complementary satiety mechanisms. AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) activates AMPK — the cellular energy-sensing enzyme — and is studied for its ability to mimic exercise-like metabolic adaptations.
Gut Hormone Peptides in Appetite and Metabolism Research
Neuropeptide Y (NPY) is the primary orexigenic peptide in the hypothalamus; drugs and peptides that suppress NPY signaling show anti-obesity potential in animal models. Peptide YY (PYY), released from L-cells after eating, suppresses appetite through Y2 receptor signaling and is studied as a satiety biomarker and potential therapeutic. GIP (Glucose-Insulinotropic Polypeptide) is the second incretin hormone and a primary target for tirzepatide's dual agonism. Oxyntomodulin, a proglucagon-derived peptide, activates both GLP-1 and glucagon receptors and is studied as a native dual agonist. Glucagon itself is included in triple-agonist designs for its thermogenic and lipolytic signaling. GLP-1 (native), the endogenous 7-36 amide form, defines the pharmacological target for the entire GLP-1 agonist drug class. Amylin, the beta-cell co-secreted peptide, regulates gastric emptying and caloric intake through area postrema signaling. Pramlintide, the synthetic amylin analogue, is FDA-approved for glucose control and studied for weight effects. LEAP-2 is an endogenous ghrelin receptor antagonist recently identified as a key counter-regulatory signal to hunger. Exenatide (Exendin-4), the first GLP-1 agonist drug, anchors the historical and mechanistic GLP-1 research timeline. Suprefort, a pancreatic peptide bioregulator, is studied for beta-cell protection in the context of type 2 diabetes and metabolic syndrome. Pancragen, a pancreatic bioregulator dipeptide, targets exocrine and endocrine pancreatic function. Fragment 176-191 is the C-terminal GH fragment studied specifically for adipocyte lipolysis without systemic GH effects.
About the Author
KnowYourPeptide Research Team
KnowYourPeptide Research Team
Content produced by the KnowYourPeptide research and editorial team. All articles are written from peer-reviewed primary literature and reviewed for scientific accuracy by credentialed researchers and a board-certified physician before publication.
Meet the full editorial teamMedically Reviewed by Dr. Amanda Reid, MD
This article has been reviewed by Dr. Amanda Reid, MD (Board-Certified Internal Medicine), Know Your Peptide Medical Advisor, for scientific accuracy, safety information, and appropriate clinical context. Learn about our review process.